MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

212.74 +2.61 (+1.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
News headline image
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says ↗
Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile. 
Via Benzinga
News headline image
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript ↗
AXSM earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
A Closer Look at 10 Analyst Recommendations For Axsome Therapeutics ↗
 
Via Benzinga
News headline image
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Breaking Down Axsome Therapeutics: 19 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About Axsome Therapeutics Stock ↗
 
Via Benzinga
News headline image
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Bargain Stocks to Buy in a Market That's Priced for Perfection ↗
Yes, bargains can still be found in the stock market. 
Via The Motley Fool
News headline image
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Unveiling 14 Analyst Insights On Axsome Therapeutics ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Axsome Therapeutics Through 9 Analysts ↗
 
Via Benzinga
News headline image
1 Under-the-Radar Biotech Stock to Buy and Hold ↗
It could be an industry giant in the making. 
Via The Motley Fool
News headline image
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
Seven presentations highlight the Company’s growing CNS portfolio and commitment to improving treatment outcomes for patients with sleep disorders 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
FDA sets PDUFA action goal date of January 31, 2025 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics to Participate in Investor Conferences in September
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
New Study Reveals How Classical Music Could Revolutionize Depression Care
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of... 
Via PressReach
News headline image
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Lithia Motors To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript ↗
AXSM earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Why Axsome Therapeutics Stock Is Sinking Today ↗
Investors were unhappy with Axsome's worse-than-expected Q2 loss. 
Via The Motley Fool
News headline image
Axsome Plunges On Wide Losses, But Its Biggest Moneymaker Tacks On 135% Growth ↗
The company makes treatments for depression and excessive daytime sleepiness. 
Via Investor's Business Daily
News headline image
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
From FN Media Group LLC
Via GlobeNewswire
News headline image
Jim Cramer Calls Axsome A 'Double Or Nothing Stock,' Says SAP Is 'Incredible' ↗
Jim Cramer discusses Torm, Trane, Sap and Axsome Therapeutics on CNBC's "Mad Money Lightning Round." 
Via Benzinga
News headline image
7 Biotech Stocks to Keep on Your Clinical Radar ↗
Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story